Abivax Publishes its Financial Results for 2024

Biotechnology company Abivax has released its financial results for 2024. Available cash as of December 31, 2024, stood at €144.2 million, ensuring funding for operations through the fourth quarter of 2025. Operating revenue increased to €12.5 million, primarily due to an increased research tax credit and increased grant funding. These increases partially offset significant research and development expenses, reaching €146.5 million, related to the progress of the phase 3 clinical trial of obefazimod for ulcerative colitis.

CEO Marc de Garidel sees 2025 as a decisive year for Abivax. Despite a higher operating loss of €172.9 million, the company is continuing its efforts to develop innovative therapies and anticipates significant clinical trial results in the third quarter of 2025. The studies are focused on achieving key results and on disciplined financial management, even with increased expenses to support organizational growth and upcoming trials.